JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

Search

Corvus Pharmaceuticals Inc

Închisă

4.43 3.75

Rezumat

Modificarea prețului

24h

Curent

Minim

4.27

Maxim

4.42

Indicatori cheie

By Trading Economics

Venit

27M

15M

Angajați

31

EBITDA

-1.8M

-9.9M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+186.08% upside

Statistici piață

By TradingEconomics

Capitalizare de piață

56M

332M

Deschiderea anterioară

0.68

Închiderea anterioară

4.43

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

Corvus Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

11 aug. 2025, 17:49 UTC

Principalele dinamici ale pieței

180 Life Sciences Stock Jumps on $156 Million Notes Sale

11 aug. 2025, 17:18 UTC

Principalele dinamici ale pieței

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

11 aug. 2025, 16:25 UTC

Câștiguri

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

11 aug. 2025, 23:50 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

11 aug. 2025, 23:42 UTC

Market Talk

Global Energy Roundup: Market Talk

11 aug. 2025, 23:42 UTC

Market Talk

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

11 aug. 2025, 23:36 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

11 aug. 2025, 23:32 UTC

Market Talk

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

11 aug. 2025, 23:02 UTC

Market Talk

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

11 aug. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

11 aug. 2025, 20:37 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

11 aug. 2025, 20:37 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Bakkt Holdings 2Q Rev $577.9M >BKKT

11 aug. 2025, 20:37 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

11 aug. 2025, 20:22 UTC

Câștiguri

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

11 aug. 2025, 20:22 UTC

Câștiguri

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

11 aug. 2025, 20:22 UTC

Câștiguri

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

11 aug. 2025, 20:22 UTC

Câștiguri

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

11 aug. 2025, 20:22 UTC

Câștiguri

Exodus Movement 2Q Rev $25.8M >EXOD

11 aug. 2025, 20:14 UTC

Market Talk

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

11 aug. 2025, 19:12 UTC

Market Talk

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

11 aug. 2025, 18:56 UTC

Market Talk

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

11 aug. 2025, 18:31 UTC

Market Talk

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

11 aug. 2025, 17:43 UTC

Market Talk

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

11 aug. 2025, 17:28 UTC

Market Talk

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

11 aug. 2025, 17:16 UTC

Market Talk

Commodity Longs Fall to 11-Month Low -- Market Talk

11 aug. 2025, 16:42 UTC

Achiziții, Fuziuni, Preluări

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

11 aug. 2025, 16:27 UTC

Achiziții, Fuziuni, Preluări

BBVA Says Sabadell Offer Remains in Effect

11 aug. 2025, 16:26 UTC

Achiziții, Fuziuni, Preluări

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

11 aug. 2025, 16:25 UTC

Achiziții, Fuziuni, Preluări

Banco de Sabadell Announced TSB Sale on July 1

11 aug. 2025, 16:25 UTC

Achiziții, Fuziuni, Preluări

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Comparație

Modificare preț

Corvus Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

186.08% sus

Prognoză pe 12 luni

Medie 12.33 USD  186.08%

Maxim 15 USD

Minim 11 USD

În baza a 4 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCorvus Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

4 ratings

4

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

3.165 / 3.5827Suport & Rezistență

Termen scurt

Strong Bearish Evidence

Termen mediu

Bearish Evidence

Termen lung

Weak Bearish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.